CA2989735C - Anticorps liant l'alpha-synucleine et utilisations connexes pour le traitement de la synucleinopathie - Google Patents

Anticorps liant l'alpha-synucleine et utilisations connexes pour le traitement de la synucleinopathie

Info

Publication number
CA2989735C
CA2989735C CA2989735A CA2989735A CA2989735C CA 2989735 C CA2989735 C CA 2989735C CA 2989735 A CA2989735 A CA 2989735A CA 2989735 A CA2989735 A CA 2989735A CA 2989735 C CA2989735 C CA 2989735C
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2989735A
Other languages
English (en)
Other versions
CA2989735A1 (fr
Inventor
Pekka Kallunki
Karina Fog
Louise Buur Vesterager
Ann-Louise Bergstrom
Florence Sotty
David Satijn
Edward VAN DEN BRINK
Paul Parren
Rik RADEMAKER
Tom Vink
Ibrahim John Malik
Liliana Christina Pereira Montezinho
Jeffrey B Stavenhagen
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1512203.9A external-priority patent/GB201512203D0/en
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CA2989735A1 publication Critical patent/CA2989735A1/fr
Application granted granted Critical
Publication of CA2989735C publication Critical patent/CA2989735C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne de nouveaux anticorps monoclonaux anti-alpha-synucléine. Les anticorps peuvent être utilisés pour traiter une synucléinopathie telle que la maladie de Parkinson (y compris les formes idiopathiques et héréditaires de la maladie de Parkinson), la maladie diffuse à corps de Lewy (DLBD), la variante à corps de Lewy de la maladie d'Alzheimer (LBV), la maladie combinée d'Alzheimer et de Parkinson, la dysautonomie pure et l'atrophie multisystème.
CA2989735A 2015-07-13 2016-07-12 Anticorps liant l'alpha-synucleine et utilisations connexes pour le traitement de la synucleinopathie Active CA2989735C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1512203.9 2015-07-13
GBGB1512203.9A GB201512203D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
PCT/EP2016/066476 WO2017009312A1 (fr) 2015-07-13 2016-07-12 Agents, utilisations et procédés pour le traitement d'une synucléinopathie

Publications (2)

Publication Number Publication Date
CA2989735A1 CA2989735A1 (fr) 2017-01-19
CA2989735C true CA2989735C (fr) 2025-09-09

Family

ID=

Similar Documents

Publication Publication Date Title
US20230312693A1 (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
US12421303B2 (en) Agents, uses and methods for the treatment of synucleinopathy
CA2989735C (fr) Anticorps liant l'alpha-synucleine et utilisations connexes pour le traitement de la synucleinopathie
HK40127009A (en) Agents, uses and methods for the treatment of synucleinopathy
HK1254358B (en) Agents, uses and methods for the treatment of synucleinopathy
OA18689A (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
BR112017027506B1 (pt) Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo, preparação, composição farmacêutica, uso dos mesmos e kit para o tratamento de sinucleinopatia